Romidepsin
Childhood Cerebellar Astrocytic Neoplasm
Floatz Rating
CCC52/100
Confidence
Indicative
Sponsor
City of Hope Medical Center
Modality
Small molecule
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00053963CT.gov FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Childhood Cerebellar Astrocytic Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Romidepsin (this asset) | City of Hope Medical Center | P1 | CCC · 52 |
| Oxaliplatin | National Cancer Institute (NCI) | P2 | B |
| Irinotecan | National Cancer Institute (NCI) | P2 | B |
| Cilengitide | National Cancer Institute (NCI) | P2 | B |
| 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- | National Cancer Institute (NCI) | P2 | CCC |
| Nivestim | City of Hope Medical Center | P1 | CCC |
| Dexasone | National Cancer Institute (NCI) | P1 | CCC |
| Vorinostat | National Cancer Institute (NCI) | P1 | CCC |
| Alvocidib | National Cancer Institute (NCI) | P1 | CC |
+11 more in the Childhood Cerebellar Astrocytic Neoplasm cohort
Other indications for Romidepsin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Myelodysplastic Syndrome | — | P4 | BB · 70 |
| Peripheral T-Cell Lymphoma, Not Otherwise Specified | — | P3 | BB · 70 |
| Burkitt Lymphoma | — | P2 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- OxaliplatinNational Cancer Institute (NCI)B
- IrinotecanNational Cancer Institute (NCI)B
- CilengitideNational Cancer Institute (NCI)B
- 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-National Cancer Institute (NCI)CCC
- NivestimCity of Hope Medical CenterCCC
Citation
Floatz Terminal. Romidepsin in Childhood Cerebellar Astrocytic Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/romidepsin-childhood-cerebellar-astrocytic-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →